MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-04-2026
Ascendis Pharma A/S Retained Earnings 2011-2026 | ASND
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Ascendis Pharma A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | -611 M | -393 M | -263 M | 159 M | 111 M | 39.6 M | 2.13 M | -1.95 M | -3.2 M |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 159 M | -611 M | -107 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Cabaletta Bio
CABA
|
-517 M | $ 3.4 | 4.29 % | $ 342 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
-6.7 B | $ 333.39 | -1.77 % | $ 43.7 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-176 M | $ 3.17 | 3.93 % | $ 5.22 M |  Israel |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.73 | 3.04 % | $ 8.97 B |  Australia |
 |
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-642 M | $ 7.42 | -15.1 % | $ 73.3 M | USA |
 |
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Applied Therapeutics
APLT
|
-469 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
667 M | $ 21.68 | 1.4 % | $ 1.01 B | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 99.47 | 1.08 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-1.68 B | - | - | $ 399 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-447 M | $ 4.24 | 2.17 % | $ 453 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-1.14 B | $ 24.58 | -2.03 % | $ 3.13 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-237 M | - | -2.5 % | $ 5.88 M | USA |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.39 B | $ 1.49 | 0.68 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
-8.32 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-100 M | $ 2.75 | 4.16 % | $ 1.22 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M | Israel |
 |
bluebird bio
BLUE
|
-4.26 B | - | - | $ 546 M | USA |
 |
AstraZeneca PLC
AZN
|
5.3 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Cidara Therapeutics
CDTX
|
-611 M | - | - | $ 1.41 B | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-265 M | - | - | $ 310 B | Britain |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
-1.62 B | $ 2.17 | 5.85 % | $ 451 M | USA |